# Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

> **NCT00761020** · NA · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 31 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Mefloquine
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT00761020
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-04
- **Final completion:** 2009-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761020, "Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00761020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*